New Zealand - English - Medsafe (Medicines Safety Authority)

celgene limited - lenalidomide 20mg;   - capsule - 20 mg - active: lenalidomide 20mg   excipient: capsule blue 3628 capsule blue-green 6579 croscarmellose sodium lactose magnesium stearate microcrystalline cellulose tekprint black sw-9008 tekprint black sw-9009 - revlimid is indicated for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplantation

New Zealand - English - Medsafe (Medicines Safety Authority)

celgene limited - lenalidomide 7.5mg;   - capsule - 7.5 mg - active: lenalidomide 7.5mg   excipient: capsugel yellow 4035 capsule white 0999 croscarmellose sodium lactose magnesium stearate microcrystalline cellulose tekprint black sw-9008 tekprint black sw-9009 - revlimid is indicated for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplantation

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

celgene ltd - thalidomide - capsule - 50mg

Israel - English - Ministry of Health

neopharm ltd - thalidomide - hard capsule - thalidomide 50 mg - thalidomide - multiple myeloma : 1. for the treatment of multiple myeloma after failure of standars therapies. 2. thalidomide celgene 50 mg hard capsules in combination with dexamethasone is indicated for the treatment of patients with newly diagnosed multiple myeloma. 3. thalidomide celgene in combination with melphalan and prednisone is indicated for the treatment of patients with untreated multiple myeloma > or = 65 years or ineligible for high dose chemotherapy. erythema nodosum leprosum: 4. for the acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum (enl). thalidomide is not indicated as monotherapy for such enl treatment in the presence of moderate to severe neuritis. it is also indicated as maintenance therapy for prevention and suppression of the cutaneous manifestations of enl recurrence.בקשה לעדכון משטר מינון 4/2/2020

New Zealand - English - Medsafe (Medicines Safety Authority)

celgene limited - pomalidomide 1mg;   - capsule - 1 mg - active: pomalidomide 1mg   excipient: gelatin indigo carmine iron oxide yellow mannitol pregelatinised maize starch sodium stearyl fumarate titanium dioxide - pomalidomide, in combination with dexamethasone, is indicated for the treatment of patients with relapsed and refractory multiple myeloma who have received at least two prior treatment regimens, including both lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy

New Zealand - English - Medsafe (Medicines Safety Authority)

celgene limited - pomalidomide 2mg;   - capsule - 2 mg - active: pomalidomide 2mg   excipient: erythrosine gelatin indigo carmine iron oxide yellow mannitol pregelatinised maize starch sodium stearyl fumarate titanium dioxide - pomalidomide, in combination with dexamethasone, is indicated for the treatment of patients with relapsed and refractory multiple myeloma who have received at least two prior treatment regimens, including both lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy

New Zealand - English - Medsafe (Medicines Safety Authority)

celgene limited - pomalidomide 3mg;   - capsule - 3 mg - active: pomalidomide 3mg   excipient: gelatin indigo carmine iron oxide yellow mannitol pregelatinised maize starch sodium stearyl fumarate titanium dioxide - pomalidomide, in combination with dexamethasone, is indicated for the treatment of patients with relapsed and refractory multiple myeloma who have received at least two prior treatment regimens, including both lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy

New Zealand - English - Medsafe (Medicines Safety Authority)

celgene limited - pomalidomide 4mg;   - capsule - 4 mg - active: pomalidomide 4mg   excipient: brilliant blue fcf gelatin indigo carmine mannitol pregelatinised maize starch sodium stearyl fumarate titanium dioxide - pomalidomide, in combination with dexamethasone, is indicated for the treatment of patients with relapsed and refractory multiple myeloma who have received at least two prior treatment regimens, including both lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy

New Zealand - English - Medsafe (Medicines Safety Authority)

celgene limited - azacitidine 100mg;   - powder for injection - 100 mg - active: azacitidine 100mg   excipient: mannitol - indicated for the treatment of patients with: - intermediate-2 and high-risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss) in whom allogenic stem cell transplantation is not indicated.

New Zealand - English - Medsafe (Medicines Safety Authority)

celgene limited - azacitidine 100mg;   - powder for injection - 100 mg - active: azacitidine 100mg   excipient: mannitol - · intermediate-2 and high-risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss) in whom allogenic stem cell transplantation is not indicated.